Our team has found that patients on concurrent GLP-1 therapy (semaglutide, tirzepatide) often benefit from twice-weekly lipo c dosage during the first 812 weeks of treatment, when caloric deficit is steepest and hepatic fat mobilisation is most active
Research reviews also describe BPC-157s protective effects in models involving NSAID-related gastrointestinal lesions, alcohol-related injury, perforated stomach lesions, esophagitis, fistula healing, intestinal inflammation, and other GI injury models
It shields skin cells from damage while simultaneously supporting the cellular processes that maintain hydration, promote collagen synthesis, and contribute to overall skin vitality
With clinical oversight, personalized dosing, and ongoing support, we help you achieve safe, sustainable weight loss while improving energy, mood, and confidence